The Top 10 bestselling orphan drugs in the USA in 2017. Celgene's Revlimid (generic name lenolidamide) leads the way with sales of USD 5.4 billion, followed by Roche's Rituxan (rituximab) with USD 4.2 billion in sales and TEVA's Copaxone (glatiramer acetate) with USD 3.1 billion. The most expensive drug in the Top 10 was Alexion's Soliris (eculizumab) for paroxysmal nocturnal hemoglobinuria (PNH). Despite only treating 2,462 patients, Alexion sold USD 1.2 billion worth of Soliris thanks to revenues of USD 501,719 per patient

Made with Visme Infographic Maker